Search

We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.

Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.

In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.

• News

Despite the challenges of the pandemic, researchers and pharmaceutical companies are still making progress towards delivering new treatments for inherited sight loss.

• News
• Leber congenital amaurosis (LCA)

Download copies of our Knowledge-base material

Inherited progressive sight loss is caused by a range of rare genetic conditions. We specialise in those which affect the retina.

A virtual delegate bag for our online attendees - Professionals' Conference 2024

Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.

• News

Rachael first noticed she had sight problems at the age of 15. She went to her local eye clinic, who said she had an astigmatism.

• Case study - community
• Written

Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.

• News
• Stargardt disease